- Press Release -

Rockville, Md. The global market for OTC cough, cold and allergy medicines is set to reach around US$ 37.323 Bn by 2022, growing at a 4.9% CAGR, according to Fact.MR. With many consumers treating minor symptoms themselves rather than seeing a doctor, these everyday remedies keep selling steadily, and busy modern routines only reinforce the habit.

Asia Pacific excluding Japan is the most attractive region, antihistamines lead by drug type, and pharmacies remain the main point of sale. A rising base of elderly and immunosuppressed patients adds another layer of demand across the forecast period.

Drugs, Channels and Dosage

Antihistamines carry more than a third of revenue in 2017, prized for easing watery eyes, runny nose, sneezing and swelling. By channel, pharmacies stay the top route to market, with drug stores second. On dosage, tablets hold a significant share and are set to reach nearly US$ 12.425 Bn by 2022, keeping their place as the format consumers reach for most.

Asia Pacific excluding Japan commands a notable revenue share, helped by dropping air quality and higher rates of respiratory illness, alongside quick uptake of convenient, low-cost OTC options.

Self-Medication Drives Demand

The market runs on convenience. As consumers weigh the time cost of a doctor's visit against a quick pharmacy purchase, self-treatment for minor ailments keeps gaining ground, and healthcare regulators in several countries have set guidelines to keep those sales safe. An ageing, more vulnerable population widens the base of buyers further.

Suppliers and Their Playbook

The field brings together large pharmaceutical and consumer health companies.

• Allergan, Bristol-Myers Squibb Co., Prestige Brands Holdings, Inc., Pfizer Inc., GlaxoSmithKline Plc., Reckitt Benckiser Group Plc., AstraZeneca Plc., Johnson & Johnson Service, Inc., Procter & Gamble Co., Sanofi-Aventis, Novartis AG, Merck & Co., and Sun Pharmaceutical Industries Ltd. are among the key players in the report.

Reading the Market for Decisions

For manufacturers, growth favours antihistamine lines and strong pharmacy distribution. Investors get a market with dependable, self-care-led demand. Procurement and retail teams can plan around pharmacies leading sales, tablets carrying volume, and Asia Pacific offering the largest opportunity through 2022.

About the Report

Fact.MR's study covers the global OTC cough, cold and allergy medicine market for the 2017 to 2022 forecast period, with segmentation by drug type, OTC channel, dosage and region. It sizes each segment, maps the competitive field, and weighs the consumer forces shaping demand. Further detail is available in the OTC cough, cold and allergy medicine market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.